LIVE

SNDX

Syndax Pharmaceuticals, Inc.

SNDX

NASDAQ·Healthcare·Biotechnology·Mkt cap $1.9B

$21.82

▲ +4.45%

View full research view

Our plain-language verdict, the thesis, risk factors, and what is changing about the business.

View research view

52-Week Range

$8.59 - $25.59

P/E

-7.79

Fwd P/E

-13.92

Beta

0.39

Div Yield

0.00%

Avg Vol

1.8M

Shares Out

88.2M

Mkt Cap

$1.9B

Price action

Price chart

Up 132.1% over the trailing year

1W
1M
3M
6M
YTD
1Y
5Y
MAX

Total returns

Price performance

Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.

Why we rate it this way

The thesis at a glance

Bull and bear case · plain-English context across the five lenses we evaluate.

▲

Bull Case

4 reasons

  • Novel Menin-MLL binding mechanism with limited competitive landscape
  • Strategic partnerships with National Cancer Institute and major pharmaceutical companies
  • Focused pipeline targeting high-unmet medical needs in oncology and immunology
  • Experienced management team in precision medicine and clinical development
▼

Bear Case

2 risks

  • Low volatility (beta 0.4).
  • Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.

Growth

Strong growth ahead

Advancement of SNDX-5613 through Phase 1/2 trials in AML indications

Value

Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.

Momentum

Weak

-16.9% over 3m

Quality

Excellent

High-growth business (397% revenue growth, 98% gross margin). Pre-profit but investing in growth.

Dividend

None

No dividend

Earnings track record

Recent earnings results

AI-summarized recap of last quarter, plus the surprise on every print.

Next: May 4, 2026

“
Q2 26 RECAP

APR 30, 2026

Reported EPS of -$0.48 vs -$0.59 consensus (+18.6% surprise). Revenue of $64.9M vs $69.8M expected (-7.0%).

EPS beat +18.6%
Revenue miss

EPS surprise · last 4Q

1 of 1 beats

Q2 26

+18.6%

Next: May 4, 2026

Revenue trend · last 8Q

—

—

—

—

+985%

+267%

+792%

+224%

Q2 24

Q3 24

Q4 24

Q1 25

Q2 25

Q3 25

Q4 25

Q1 26

$3.5M

$12.5M

$7.7M

$20.0M

$38.0M

$45.9M

$68.5M

$64.9M

Margins · last 8Q

Gross

—

Operating

—

Profit

-65.8%

View full earnings history →

Wall Street consensus

8 analysts · 100% Buy

Live ratings and price targets aggregated across covering analysts.

Buy

8

100%

Hold

0%

Sell

0%

Median Price Target

$40.00

▲ +83.3% vs $21.82

Low $37.00
Median $40.00
High $46.00

Latest: Guggenheim · Jun 12, 2026

3 analysts covering

View full analyst page →

vs Industry

How SNDX stacks vs Biotechnology

Stock metrics vs industry averages. Green = better than industry.

Industry comparison data unavailable for this stock.